BTGGF - BTG plc

Other OTC - Other OTC Delayed price. Currency in USD
9.15
0.00 (0.00%)
At close: 9:49AM EDT
Stock chart is not supported by your current browser
Previous close9.15
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume0
Avg. volume2,693
Market cap3.45B
Beta0.19
PE ratio (TTM)82.43
EPS (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • Reuters12 days ago

    BTG to buy Roxwood Medical for up to $80 million

    Roxwood's portfolio of anchoring catheters and microcatheters for treatment of complex cardiovascular lesions should leverage BTG's existing successful EKOS (endovascular system) sales and marketing operation, Deutsche Bank analysts said in a note. Separately, BTG stuck to its double-digit product sales growth forecast, adding that licensing revenue in the first half has benefited from back royalties on Lemtrada, Sanofi's (SASY.PA) multiple sclerosis treatment. BTG said licensing revenue is expected to decline over the full year by low double digits at constant currency, compared to a previous forecast of a high-teens decline.

  • Reuters - UK Focus11 months ago

    BTG unit pleads guilty in U.S. to misbranding, to pay $36 mln

    A U.S. unit of British drug company BTG Plc pleaded guilty on Monday to a misdemeanor related to its misbranding of the embolic device LC Bead, and will pay about $36 million to resolve its criminal and ...

  • We're sorry this is all we were able to find about this topic.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes